Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
GERMANTOWN, Md., Jan. 04, 2018 -- Orgenesis Inc., (OTCQB:ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experience in gene and cell therapy and regenerative medicine, today announced that it will be presenting at the Biotech Showcase in San Francisco, CA being held on January 8-10, 2018. Vered Caplan, Chief Executive Officer of Orgenesis, will be giving a presentation and meeting with investors.
Event: Biotech Showcase™
Presentation Date: Tuesday, January 9, 2018
Presentation Time: 3:00pm PT
Location: Hilton San Francisco Union Square, San Francisco, CA
For investors attending the Biotech Showcase, please contact Orgenesis' Investor Relations at [email protected] to schedule a meeting with management.
The presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the Investors’ presentations tab of the Investors’ section of the Orgenesis website at www.orgenesis.com.
About Orgenesis Inc.
Orgenesis is a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing. Through its Israeli subsidiary, Orgenesis Ltd., Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs). Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. Through its Belgian subsidiary, MaSTherCell S.A., a global Contract Development and Manufacturing Organization (CDMO), Orgenesis is able to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market. From technology selection to business modeling, GMP manufacturing, process development, quality management and assay development, MaSTherCell's teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. MaSTherCell operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin. This integrated approach supports the Company's business philosophy of bringing to market significant life-improving medical treatments. For more information, visit www.orgenesis.com.
Contacts
Edison Advisors (investors)
Tirth Patel
(646) 653-7035
[email protected]
